• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

ADA 2026

Abbott studies reinforce DKA opportunity following dual sensor milestone

June 6, 2026 By Sean Whooley

Abbott Libre Duo dual glucose-ketone sensor CGM

Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Hospital Care, Patient Monitoring, Technology Tagged With: abbott, ADA 2026

Insulet data backs Omnipod 6, fully closed-loop AID systems

June 6, 2026 By Sean Whooley

Insulet Omnipod 5 with iphone

Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: ADA 2026, Insulet

Tidepool data highlights automated insulin delivery algorithm enhancements, women’s health initiative

June 6, 2026 By Sean Whooley

Tidepool Loop automated insulin delivery software

Tidepool has new clinical insights and research initiatives related to diabetes management and automated insulin delivery (AID) technology. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It developed the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) AID system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Patient Monitoring, Technology Tagged With: ADA 2026, tidepool

MannKind shares more data backing inhaled insulin

June 5, 2026 By Sean Whooley

MannKind Afrezza inhaler for insulin

MannKind (Nasdaq:MNKD) today announced new clinical findings for its Afrezza inhaled insulin powder and Furoscix furosemide injection. The company shared outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. MannKind’s Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: ADA 2026, mannkind

Tandem wins CE mark for automated insulin delivery in type 2 diabetes, pregnancy

June 5, 2026 By Sean Whooley

Tandem Diabetes Care Mobi Lifestyle

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received expanded CE mark for its automated insulin delivery (AID) systems. San Diego-based Tandem can now bring its Control-IQ-powered AID systems — the flagship t:slim X2 and miniature Mobi — to European adults with type 2 diabetes and those with type 1 diabetes during pregnancy. Approval in […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Regulatory/Compliance, Technology, Women's Health Tagged With: ADA 2026, Tandem Diabetes Care

Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app

June 4, 2026 By Sean Whooley

Dexcom CGM lifestyle

Dexcom (Nasdaq:DXCM) announced today that entered into an agreement to acquire Nutrisense and shared plans for upgrades to its Stelo sensor. San Diego-based Dexcom expects its deal to buy Nutrisense for an undisclosed amount in the coming weeks. With the acquisition, the continuous glucose monitor (CGM) maker plans to further expand its ability to support […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: ADA 2026, Dexcom

CeQur announces extended wear time, added dosing for mealtime insulin patch pump

June 4, 2026 By Sean Whooley

CeQur Simplicity insulin delivery patch (1)

CeQur announced today that it picked up two recent FDA clearances for its Simplicity mealtime insulin patch pump system. The FDA cleared Simplicity for an extended wear time of up to seven days and gave the green light to a new 1-unit (1U) device. Additionally, Horw, Switzerland-based CeQur plans to share two clinical posters at […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: ADA 2026, cequr

  • « Go to Previous Page
  • Page 1
  • Page 2

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS